IndiGo Reports Stabilized Operations, Prepared for Holiday Travel Influx

On Wednesday, December 24, IndiGo announced that it has successfully stabilized its operations and is ready to accommodate the anticipated increase in passenger demand during the current holiday season.

An IndiGo representative stated that since December 9, 2025, the airline has been gradually increasing its capacity in line with government regulations and is currently conducting between 2,100 and 2,200 flights each day. IndiGo is transporting over one million passengers every three days throughout its network, serving all 138 operational destinations while upholding its on-time performance standards.

The airline noted that it has effectively addressed the recent operational challenges faced by the aviation industry, particularly due to dense fog in northern India, which caused widespread disruptions. Although IndiGo was affected, it managed its operations expertly to ensure overall stability.

With weather predictions suggesting a more severe winter ahead, the airline is committed to ensuring reliability and minimizing disruptions across its network to lessen any inconvenience for passengers.

First Airbus A321XLR aircraft

Looking forward, IndiGo is preparing to introduce its first Airbus A321XLR aircraft, expected to improve medium- to long-haul connectivity for travelers in India and the subcontinent. The airline plans to use the aircraft on routes connecting Delhi and Mumbai with Athens starting January 23, 2026, as previously announced.

IndiGo also mentioned that it is assessing additional domestic and international destinations in alignment with its fleet expansion initiatives and will provide further updates in due course. The airline expressed gratitude to its customers for their ongoing trust and reaffirmed its commitment to enhancing connectivity within India and to significant global destinations.

Shares of IndiGo’s parent company, Interglobe Aviation, closed lower at ₹5080.90 on the BSE today.

Also Read: Strides Pharma US unit receives 4 observations following FDA inspection, reports no supply impact